Skip to main content
Clinical Trials/EUCTR2013-005435-24-NL
EUCTR2013-005435-24-NL
Active, not recruiting
Phase 1

Treatment strategies in colorectal cancer patients with initially irresectable liver-only metastases. CAIRO5 a randomized phase 3 study of the Dutch Colorectal Cancer Group (DCCG) - CAIRO5

Dutch Colorectal Cancer Group0 sites584 target enrollmentFebruary 4, 2014

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Dutch Colorectal Cancer Group
Enrollment
584
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 4, 2014
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Dutch Colorectal Cancer Group

Eligibility Criteria

Inclusion Criteria

  • \-Histologically proven colorectal cancer
  • \-Irresectable metastases confined to the liver according to CT scan, obtained \= 4 weeks prior to randomization. Irresectability should be confirmed by the panel. Patients with small (\= 1 cm) extrahepatic lesions that are not clearly suspicious of metastases are eligible.
  • \-Adequate tumor tissue available for central assessment of RAS/BRAF mutation status
  • \-WHO performance status 0\-2 (Karnofsky performance \= 70\)
  • \-Age \= 18 years
  • \-No contraindications for liver surgery
  • \-in case of synchronous metastatses: resectable primary tumor, or adequate clinical recovery in case of immediate surgery of primary tumor
  • \-Adequate organ functions, as determined by normal bone marrow function (Hb ³ 6\.0 mmol/L, absolute neutrophil count ³ 1\.5 x 109/L, platelets ³ 100 x 109/L), renal function (serum creatinine \= 1\.5x ULN and creatinine clearance, Cockroft formula, ³ 30 ml/min), liver function (serum bilirubin \= 2 x ULN, serum transaminases \= 5x ULN)
  • \-Life expectancy \> 12 weeks
  • \-Expected adequacy of follow\-up

Exclusion Criteria

  • \-Extrahepatic metastases, with the exception of small (\= 1 cm) extrahepatic lesions that are not clearly suspicious of metastases
  • \-Irresectable primary tumor, or resectable tumor requiring immediate surgery
  • \-Serious comorbidity or any other condition preventing the safe administration of study treatment (including both systemic treatment and surgery)
  • \-Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months of randomization
  • \-Uncontrolled hypertension, or unsatisfactory blood pressure control with \=3 antihypertensive drugs
  • \-Previous systemic treatment for metastatic disease; previous adjuvant treatment is allowed if completed \= 6 months prior to randomization
  • \-Previous intolerance of study drugs in the adjuvant setting
  • \-Pregnant or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases. CAIRO5 a randomized phase 3 study of the Dutch Colorectal Cancer Group (DCCG)Bowel CancerColorectal cancer10017991
NL-OMON54605Dutch Colorectal Cancer Group584
Completed
Not Applicable
A Real-world, Retrospective Observational Study of Targeted Therapy in Metastatic Colorectal CancerHealth Condition 1: C260- Malignant neoplasm of intestinal tract, part unspecified
CTRI/2023/09/057410Dr. Reddy’s Laboratories Ltd.100
Recruiting
Not Applicable
Treatment of Recurrent and Advance Colorectal Cancer (TRACC): A prospective multi-site registryAdvanced Colorectal Cancer
ACTRN12618000404224Biogrid3,000
Completed
Not Applicable
Chemotherapy choices in advanced colorectal cancer - a randomised trial comparing two durations and three chemotherapy regimens in the palliative treatment of advanced colorectal cancer
ISRCTN82942120Medical Research Council (MRC) (UK)905
Active, not recruiting
Phase 1
Treatment of bowel cancer using a different approach than surgery using a new device that makes the tumor absorb more drug while leaving the healthy tissue alone.Colorectal cancerMedDRA version: 17.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: HLTClassification code 10010039Term: Colorectal and anal neoplasms malignancy unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: HLTClassification code 10010023Term: Colorectal neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: HLTClassification code 10010040Term: Anal and colorectal neoplasms NECSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001248-23-DKAll Ireland Cooperative Oncology Research Group30